{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-094724","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.878328+00:00","generated_at":"2026-05-17T05:14:55.951290+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ocular Therapeutix updates AXPAXLI trials: SOL-1 topline Q1 2026, SOL-R H1 2027; initiates NPDR Phase 3","bullets":["SOL-1 Phase 3 wet AMD trial topline results expected Q1 2026; retention >95%, rescue events >95% meet criteria, no new safety signals.","SOL-R Phase 3 wet AMD trial enrollment completed, randomization ongoing; topline results expected H1 2027.","Plans to initiate SOL-X long-term extension trial following SOL-1/SOL-R; subjects receive AXPAXLI every 24 weeks for 3 years.","Initiates Phase 3 NPDR program with HELIOS-2 (432 subjects) and HELIOS-3 (930 subjects); FDA SPA agreement for HELIOS-2 design.","Received notice of allowance from USPTO for patent covering treating ocular diseases with AXPAXLI; expiration expected 2044."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-094724","json":"https://secwatch.observer/filing/0001104659-25-094724.json","markdown":"https://secwatch.observer/filing/0001104659-25-094724.md","text":"https://secwatch.observer/filing/0001104659-25-094724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/0001104659-25-094724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/tm2527344d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:14:55.951290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}